Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Infectious Diseases

• Publication date

  2016-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jiv762PMID 26704612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of a tetravalent dengue vaccine in children in Latin America.

  2015cited by this paper
• Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America.

  2015cited by this paper
• Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

  2015cited by this paper
• Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010

  2015cited by this paper
• Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials.

  2014cited by this paper
• Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

  2014cited by this paper
• Vaccine-Mediated Immunity Against Dengue and the Potential for Long-Term Protection Against Disease

  2014cited by this paper
• Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

  2014cited by this paper
• Identifying protective dengue vaccines: guide to mastering an empirical process.

  2013cited by this paper
• Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

  2013cited by this paper
• The global distribution and burden of dengue

  2013cited by this paper
• Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

  2012cited by this paper
• Current concepts: Dengue

  2012cited by this paper
• Clinical Features of Dengue in a Large Vietnamese Cohort: Intrinsically Lower Platelet Counts and Greater Risk for Bleeding in Adults than Children

  2012cited by this paper
• Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.

  2011cited by this paper
• Critical issues in dengue vaccine development

  2011cited by this paper
• Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

  2011cited by this paper
• Dengue: a continuing global threat

  2010cited by this paper
• Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All

  2006cited by this paper
• Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine.

  2006cited by this paper
• Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand

  2004cited by this paper
• Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

  2003cited by this paper
• The future of dengue vaccines.

  2002cited by this paper
• Dengue: an update.

  2002cited by this paper
• Research on dengue during World War II.

  1952cited by this paper

• Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific.

  2025cites this paper
• TAK-003: development of a tetravalent dengue vaccine

  2025cites this paper
• Latin America’s Dengue Outbreak Poses a Global Health Threat

  2025cites this paper
• Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.

  2025cites this paper
• Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis

  2024influential citation
• Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination

  2024cites this paper
• Current status of the development of dengue vaccines

  2024cites this paper
• Emerging Infectious Diseases and the Eye: Ophthalmic Manifestations, Pathogenesis, and One Health Perspectives

  2024cites this paper
• Effectiveness and safety of the tetravalent TAK-003 dengue vaccine: a systematic review.

  2024cites this paper
• A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health

  2024cites this paper
• Integrated One Health strategies in Dengue

  2024cites this paper
• Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study

  2023cites this paper
• An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

  2023cites this paper
• Novel approaches for the rapid development of rationally designed arbovirus vaccines

  2023cites this paper
• A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.

  2023cites this paper
• Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development

  2023cites this paper
• Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

  2022cites this paper
• Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.

  2022cites this paper
• Reply to de Silva and White

  2022cites this paper
• Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System

  2022cites this paper
• Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach

  2022cites this paper
• A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate

  2022cites this paper
• Host immunity and vaccine development against Dengue virus

  2022cites this paper
• Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques

  2021cites this paper
• Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

  2021cites this paper
• Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques

  2021cites this paper
• Updates on Dengue Vaccine and Antiviral: Where Are We Heading?

  2021cites this paper
• Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

  2021cites this paper
• Recent Insights Into the Molecular Mechanism of Toll-Like Receptor Response to Dengue Virus Infection

  2021cites this paper
• Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City

  2021cites this paper
• Characterization of the type-specific and cross-reactive B cell responses elicited by a live-attenuated tetravalent dengue vaccine.

  2020cites this paper
• Dengue: Status of current and under‐development vaccines

  2020cites this paper
• Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial

  2020cites this paper
• Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.

  2020cites this paper
• Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.

  2020cites this paper
• Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade

  2020cites this paper
• Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.

  2020cites this paper
• Role of Immunoinformatics in Accelerating Epitope-Based Vaccine Development against Dengue Virus

  2020cites this paper
• Tetravalent Dengue Vaccine in Healthy Children.

  2020cites this paper
• Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

  2020cites this paper
• Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study

  2020cites this paper
• Dengue: A Minireview

  2020cites this paper
• An update on dengue vaccine development, challenges, and future perspectives

  2020cites this paper
• Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.

  2020cites this paper
• Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

  2020cites this paper
• Title: Dengue: status of current and under-development vaccines. Running head: Dengue vaccines pipeline

  2020cites this paper
• Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial.

  2019cites this paper
• Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice

  2019cites this paper
• Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate.

  2019cites this paper
• Dengue vaccine: Global development update.

  2019cites this paper
• Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003

  2019cites this paper
• Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review.

  2019cites this paper
• Development of Peptide Vaccines in Dengue

  2018influential citation
• Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.

  2018cites this paper
• Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses.

  2018cites this paper
• Dengue: a growing threat requiring vaccine development for disease prevention

  2018cites this paper
• Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate

  2018cites this paper
• Current management of severe dengue infection

  2017cites this paper
• Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.

  2017cites this paper
• Encouraging results but questions remain for dengue vaccine.

  2017cites this paper
• First evidence of dengue infection in domestic dogs living in different ecological settings in Thailand

  2017cites this paper
• PROJECTED IMPACT OF CYD-TDV ON DENGUE BURDEN

  2017cites this paper
• Dengue vaccines: implications for dengue control

  2017cites this paper
• Recent advances in human flavivirus vaccines.

  2017cites this paper
• Immune correlates of protection for dengue: State of the art and research agenda.

  2017cites this paper
• Towards development of a universal dengue vaccine - How close are we?

  2017cites this paper
• Vaccines licensed and in clinical trials for the prevention of dengue

  2017influential citation
• Dengue Virus and Other Flaviviruses (Zika): Biology, Pathogenesis, Epidemiology, and Vaccine Development

  2017cites this paper
• Development of live-attenuated dengue vaccine

  2017cites this paper
• Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

  2017cites this paper
• Moving forward with Takeda's live chimeric tetravalent dengue vaccine.

  2017cites this paper
• Vaccines and immunization strategies for dengue prevention

  2016cites this paper
• Zika Virus: Immunity and Vaccine Development

  2016cites this paper
• Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment

  2016cites this paper
• A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone

  2016cites this paper
• Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus

  2016cites this paper
• Prospects for dengue vaccines for travelers

  2016cites this paper
• The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits

  2016cites this paper
• : Status of current and under-development vaccines. Reviews in Medical Virology, e2101. Advance online

  year unknowncites this paper
• Eficacia y seguridad de las nuevas vacunas contra el dengue Efficacy and

  year unknowncites this paper